Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases.
about
Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.Preclinical and first-in-human phase I studies of KW-2450, an oral tyrosine kinase inhibitor with insulin-like growth factor receptor-1/insulin receptor selectivityThe p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer.CSF-1/CSF-1R axis is associated with epithelial/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer.
P2860
Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Antitumor Activity of KW-2450 ...... biting Aurora A and B Kinases.
@ast
Antitumor Activity of KW-2450 ...... biting Aurora A and B Kinases.
@en
type
label
Antitumor Activity of KW-2450 ...... biting Aurora A and B Kinases.
@ast
Antitumor Activity of KW-2450 ...... biting Aurora A and B Kinases.
@en
prefLabel
Antitumor Activity of KW-2450 ...... biting Aurora A and B Kinases.
@ast
Antitumor Activity of KW-2450 ...... biting Aurora A and B Kinases.
@en
P2093
P2860
P50
P1476
Antitumor Activity of KW-2450 ...... biting Aurora A and B Kinases.
@en
P2093
Chandra Bartholomeusz
Debu Tripathy
Gabriel N Hortobagyi
Hiroko Masuda
Kazuharu Kai
Kimie Kondo
Mary K Pitner
Naoto T Ueno
Subrata Sen
Xiaoping Wang
P2860
P304
P356
10.1158/1535-7163.MCT-15-0096
P577
2015-10-06T00:00:00Z